Mirzotamab clezutoclax

{
  "id": "MLC-T-ONC-015202",
  "term": "Mirzotamab clezutoclax",
  "field": "Oncology and biomedicine",
  "definition": "An antibody-drug conjugate (ADC) composed of a monoclonal antibody against the immunoregulatory protein B7-homologue 3 (B7-H3, CD276) conjugated, via a solubilizing linker, to a B-cell lymphoma extra long (Bcl-XL) inhibitor, with potential antineoplastic activity. Upon administration of mirzotamab clezutoclax, the anti-B7-H3 monoclonal antibody moiety targets and binds to B7-H3 expressed on tumor cells. Upon binding, internalization and linker cleavage, the Bcl-XL inhibitor targets, binds to and inhibits the activity of the pro-survival protein Bcl-XL. This restores apoptotic processes and inhibits the proliferation of B7-H3-expressing tumor cells. B7-H3, a type I transmembrane protein and a member of the B7 co-stimulatory protein superfamily, is overexpressed on certain tumor cell types and on various immune cells. It plays a key role in tumor growth and immune responses.",
  "synonyms": [
    "ADC ABBV-155",
    "antibody-drug conjugate ABBV-155"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/mirzotamab-clezutoclax/"
}